Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Royalty Pharma Plc Cl A 110 East 59th Street New York NY 10022 USA

www.royaltypharma.com Employees: 99 P: 212-883-0200

Sector:

Medical

Description:

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.

Key Statistics

Overview:

Market Capitalization, $K 22,160,164
Enterprise Value, $K 28,843,554
Shares Outstanding, K 577,238
Annual Sales, $ 2,264 M
Annual Net Income, $ 858,980 K
Last Quarter Sales, $ 609,290 K
Last Quarter Net Income, $ 288,220 K
EBIT, $ 1,533 M
EBITDA, $ 1,552 M
60-Month Beta 0.47
% of Insider Shareholders 18.90%
% of Institutional Shareholders 54.35%
Float, K 468,140
% Float 81.10%
Short Volume Ratio 0.53

Growth:

1-Year Return 52.28%
3-Year Return -4.53%
5-Year Return -13.54%
5-Year Revenue Growth 24.77%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.17 on 11/05/25
Next Earnings Date 02/10/26
Earnings Per Share ttm 4.52
EPS Growth vs. Prev Qtr 2.63%
EPS Growth vs. Prev Year 12.50%
Annual Dividend & Yield 0.88 (2.29%)
Annual Dividend & Yield (Fwd) 0.88 (2.27%)
Most Recent Dividend 0.220 on 11/14/25
Next Ex-Dividends Date 11/14/25
Dividend Payable Date 12/10/25
Dividend Payout Ratio 19.48%

RPRX Ratios

Ratio
Price/Earnings ttm 8.59
Price/Earnings forward 8.40
Price/Earnings to Growth 2.05
Return-on-Equity % 26.36%
Return-on-Assets % 14.08%
Profit Margin % 37.95%
Debt/Equity 0.93
Price/Sales 9.90
Price/Cash Flow 9.25
Price/Book 2.34
Book Value/Share 16.62
Interest Coverage 6.90

RPRX Dividends

Date Value
11/14/25 $0.2200
08/15/25 $0.2200
05/16/25 $0.2200
02/21/25 $0.2200
11/15/24 $0.2100
08/16/24 $0.2100
05/16/24 $0.2100
02/15/24 $0.2100
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar